Interleukin‐6 serum levels in patients with gynecological tumors
Authors:
- 1 May 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 57 (3) , 318-323
Abstract
Serum levels of IL‐6 were evaluated in a large group of patients with benign or malignant gynecological tumors. The results obtained were correlated with the patients' clinicopathological features and follow‐up data. Using a highly sensitive immunoenzymatic method for the evaluation of serum IL‐6 levels, we observed that > 5% of normal healthy women exhibited values within the range of 1.9‐6 pg/ml. Using a cut‐off of pg/ml, elevated levels of serum IL‐6 were found in 53% of 45 patients with primary epithelial ovarian cancer and less frequently in patients with endometrial and cervical cancer (37% and 10% respectively). Elevated levels of IL‐6 were occasionally seen in patients with benign disease. IL‐6 serum levels appeared to be less sensitive than CA 125 in ovarian cancer diagnosis. In cancer patients, increased IL‐6 serum levels were related to the presence of the tumor since all post‐operative patients exhibited a marked decrease. In patients with advanced ovarian cancer post‐operative levels of IL‐6 correlated with residual disease. Very high levels of IL‐6 were observed in the ascitic fluid of9 ovarian cancer patients, but IL‐6 mRNA was not detected in tumor cells. This suggests that the increased production of IL‐6 observed in ovarian cancer is reactive. Higher levels of IL‐6 were found in patients unresponsive to chemotherapy, as compared with responsive ones. Univariate analysis of survival data suggests that increased IL‐6 serum levels correlate with negative prognosis.Keywords
This publication has 15 references indexed in Scilit:
- Tumor-Derived Products Induce Il-1 a, Il-1 b, Tnf a, and Il-6 Gene Expression in Murine Macrophages: Distinctions Between Tumor- and Bacterial Endotoxin-Induced Gene ExpressionJournal of Leukocyte Biology, 1991
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991
- The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapyAmerican Journal of Obstetrics and Gynecology, 1991
- Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignanciesBritish Journal of Cancer, 1990
- Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.Proceedings of the National Academy of Sciences, 1990
- IL‐1 and IL‐6 release by tumor‐associated macrophages from human ovarian carcinomaInternational Journal of Cancer, 1989
- Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.Journal of Experimental Medicine, 1989
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989
- The biology of interleukin-6Blood, 1989
- Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasmsInternational Journal of Cancer, 1983